Arca
Skip to content
Tools
Tools

Label Changes: Tagrisso (osimertinib mesylate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Tagrisso label DailyMed has published, from AstraZeneca Pharmaceuticals LP, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 33
  • Sections changed, version 36 to 37: 7

What changed from version 36 to version 37

Apr 22, 2026 to Sep 25, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · punctuation or symbols only
  2. Dosage and administrationChanged · 9 words added
  3. Warnings and precautionsChanged · 143 words added, 1 removed
  4. Adverse reactionsChanged · 32 words added, 12 removed
  5. Drug interactionsChanged · 1 word added, 1 removed
  6. Clinical studiesChanged · 122 words added, 64 removed
  7. Patient counseling informationChanged · 145 words added, 300 removed

Indications and usage

Changedpunctuation or symbols only
7 unchanged lines
1.4 First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC
TAGRISSO in combination with pemetrexed and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ].
1.5 Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC
1 unchanged line

Dosage and administration

Changed9 words added
13 unchanged lines
Adjuvant Treatment of EGFR Mutation-Positive NSCLC [see Indications and Usage (1.1)] | TAGRISSO monotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Tumor
Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC [see Indications and Usage (1.2) ] | Following completion of platinum-based chemoradiation therapy, TAGRISSO monotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Tumor
First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC [see Indications and Usage (1.3)] | TAGRISSO monotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Plasma or tumor
First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC [see Indications and Usage (1.4) ] | TAGRISSO in combination with pemetrexed and platinum-based chemotherapy | EGFR exon 19 deletions or exon 21 L858R mutations | Plasma or tumor
Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC [see Indications and Usage (1.5)] | TAGRISSO monotherapy | EGFR T790M Mutation | Plasma or tumor
29 unchanged lines
Blood and bone marrow [see Warnings and Precautions (5.7)] | Aplastic anemia | Withhold TAGRISSO if aplastic anemia is suspected and permanently discontinue if confirmed.
Other [[see Warnings and Precautions (5.8), see Adverse Reactions (6.1)] | Adverse reaction of Grade 3 or greater severity | Withhold TAGRISSO for up to 3 weeks.
If improvement to baseline or to Grade 0-2 within 3 weeks | Resume at 80 mg or 40 mg daily.
If no improvement within 3 weeks | Permanently discontinue TAGRISSO.
4 unchanged lines

Warnings and precautions

Changed143 words added, 1 removed
7 unchanged lines
In the LAURA study, following definitive platinum-based chemoradiation therapy, ILD/pneumonitis, including radiation pneumonitis, occurred in 80 of the 143 patients (56%) who received TAGRISSO monotherapy and 28 of the 73 patients (38%) who received placebo. There was one fatal case (0.7%), 3.5% Grade 3, 34% Grade 2, and 18% Grade 1 adverse reactions of ILD/pneumonitis in TAGRISSO-treated patients. For TAGRISSO-treated patients, ILD/pneumonitis led to permanent discontinuation of TAGRISSO in 7% of patients and dosage interruptions of TAGRISSO in 35% of patients. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD/pneumonitis. In the 80 TAGRISSO-treated patients, ILD/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%.
For patients receiving TAGRISSO who have not received recent definitive platinum-based chemoradiation therapy, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening or respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed [see Dosage and Administration (2.5) and Adverse Reactions (6.1) ].
For patients who have received recent definitive platinum-based chemoradiation therapy with Grade 1 ILD/pneumonitis continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade ≥2 ILD/pneumonitis [see Dosage and Administration (2.5) and Adverse Reactions (6.1) ].
5.2 QTc Interval Prolongation
TAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation. Of the 1813 patients treated with TAGRISSO monotherapy in clinical trials, 1.1% were found to have a QTc >500 msec, and 4.3% of patients had an increase from baseline QTc >60 msec [see Clinical Pharmacology (12.2) ].
Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc >500 msec, and 10.5% of patients had an increase from baseline QTc >60 msec.
16 unchanged lines
5.7 Aplastic Anemia
Aplastic anemia has been reported in patients treated with TAGRISSO in clinical trials (0.06% of 1813) and postmarketing [see Postmarketing (6.2) ] . Some cases had a fatal outcome. Inform patients of the signs and symptoms of aplastic anemia including but not limited to, new or persistent fevers, bruising, bleeding, and pallor. If aplastic anemia is suspected, withhold TAGRISSO and obtain a hematology consultation. If aplastic anemia is confirmed, permanently discontinue TAGRISSO [see Dosage and Administration (2.5) ] .
Perform complete blood count with differential before starting TAGRISSO, periodically throughout treatment, and more frequently if indicated.
5.8 Myalgia or Myositis with Creatine Phosphokinase Elevation
In the pooled safety population [see Adverse Reactions (6.1)], myalgia occurred in 4.8% of patients who received TAGRISSO as a monotherapy (N=1813), of these 0.1% were Grade 3. Myalgia with concurrent increased creatine phosphokinase (CPK) elevation occurred in 0.1% of patients. The median time to onset of myalgia for these patients with CPK elevation was 648 days (range: 141 days to 1155 days). Grade 1 myositis occurred in 0.2% of patients who received TAGRISSO.
Rhabdomyolysis has been reported in the post marketing setting.
Advise patients to report unexplained muscle pain or tenderness. Monitor CPK levels periodically during treatment with TAGRISSO and as clinically indicated in patients reporting unexplained muscle pain or tenderness. Withhold, then resume at the same or reduced dose [see Dosage and Administration (2.5)].
5.89 Embryo-Fetal Toxicity
Based on data from animal studies and its mechanism of action, TAGRISSO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, osimertinib caused post-implantation fetal loss when administered during early development at a dose exposure 1.5 times the exposure at the recommended clinical dose. When males were treated prior to mating with untreated females, there was an increase in preimplantation embryonic loss at plasma exposures of approximately 0.5 times those observed at the recommended dose of 80 mg once daily. Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the last dose [see Use in Specific Populations (8.1 and 8.3)].

Adverse reactions

Changed32 words added, 12 removed
8 unchanged lines
•Aplastic Anemia [see Warnings and Precautions (5.7)]
•Myalgia or Myositis with Creatine Phosphokinase Elevation [see Warnings and Precautions (5.8)]
6.1 Clinical Trials Experience
48 unchanged lines
Locally Advanced, Unresectable (Stage III) EGFR Mutation Positive NSCLC
The safety of TAGRISSO was evaluated in LAURA, a double -blind, randomized (2:1), placebo -controlled study conducted in 216 patients with EGFR exon 19 deletions or exon 21 L858R mutation -positive, locally advanced, unresectable (stage III) NSCLC, who had not progressed during or following definitive platinum -based chemoradiation therapy. Among patients who received TAGRISSO, 81% were exposed for 6 months or longer and 74% were exposed for one year or longer.
Serious adverse reactions were reported in 38% of patients treated with TAGRISSO. The most common serious adverse reactions (≥1%) included ILD/pneumonitis (13%), pneumonia (6%) and gastroenteritis (1.4%). Fatal adverse reactions occurred in 1.4% of patients who received TAGRISSO due to pneumonia (0.7%) and ILD/pneumonitis (0.7%).
159 unchanged lines
Other Clinical Trials Experience
The following adverse reactionreactions hashave been reported following administration of TAGRISSO: increased blood creatine phosphokinase and myositis.
6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of TAGRISSO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
o Skin and subcutaneous tissue: Erythema multiformeMultiforme major (EMM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), cutaneous vasculitis, erythema dyschromicum perstans o Blood and lymphatic system disorders: Aplastic anemia.
Blood and lymphatic system disorders: Aplastic anemia
Respiratory, thoracic and mediastinal disorders: Eosinophilic pneumonia

Drug interactions

Changed1 word added, 1 removed
8 unchanged lines
7.3 Drugs That Prolong the QTc Interval
The effect of co-administering medicinal products known to prolong the QTc interval with TAGRISSO is unknown. When feasible, avoid concomitant administration of drugs known to prolong the QTc interval with known risk of Torsades de pointes. If not feasible to avoid concomitant administration of such drugs, conduct periodic ECG monitoring [see Warnings and Precautions (5.32) and Clinical Pharmacology (12.2)].

Clinical studies

Changed122 words added, 64 removed
47 unchanged lines
The efficacy of TAGRISSO was demonstrated in a randomized, multicenter, double-blind, active-controlled trial (FLAURA [NCT02296125]) in patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive, metastatic NSCLC, who had not received previous systemic treatment for metastatic disease. Patients were required to have measurable disease per RECIST v1.1, a WHO performance status of 0-1, and EGFR exon 19 deletions or exon 21 L858R mutation in tumor prospectively identified by the cobas® EGFR Mutation Test in a central laboratory or by an investigational assay at a CLIA-certified or accredited laboratory. Patients with CNS metastases not requiring steroids and with stable neurologic status for at least two weeks after completion of definitive surgery or radiotherapy were eligible. Patients were assessed at the investigator’s discretion for CNS metastases if they had a history of, or suspected, CNS metastases at study entry.
Patients were randomized (1:1) to receive TAGRISSO 80 mg orally once daily or to receive gefitinib 250 mg orally once daily or erlotinib 150 mg orally once daily until disease progression or unacceptable toxicity. Randomization was stratified by EGFR mutation type (exon 19 deletions or exon 21 L858R mutation) and ethnicity (Asian or non-AsianOther races). Patients randomized to the control arm were offered TAGRISSO at the time of disease progression if tumor samples tested positive for the EGFR T790M mutation. The major efficacy outcome measure was progression-free survival (PFS), as assessed by investigator. Additional efficacy outcome measures included OS and overall response rate (ORR).
A total of 556 patients were randomized to TAGRISSO (n=279) or to control (gefitinib n=183; erlotinib n=94). The median age was 64 years (range 26-93 years); 54% were <65 years of age; 63% were female; 62% were Asian and 64% were never smokers. Baseline WHO performance status was 0 (41%) or 1 (59%); 5% had Stage IIIb and 95% had Stage IV; and 7% received prior systemic cytotoxic chemotherapy as neoadjuvant or adjuvant therapy. With regard to EGFR tumor testing, 63% were exon 19 deletions and 37% were exon 21 L858R; 5 patients (<1%) also had a concomitant de novo T790M mutation. EGFR mutation status was confirmed centrally using the cobas® EGFR Mutation Test in 90% of patients. At the time of the final data cut-off, of those randomized to TAGRISSO and to investigator’s choice erlotinib or gefitinib arm, 133 (48%) and 180 (65%) patients had received at least one subsequent treatment, respectively. Out of the 180 patients randomized to erlotinib or gefitinib who received subsequent treatment, 85 (47%) patients received TAGRISSO as first subsequent therapy.
FLAURA demonstrated a statistically significant improvement in PFS for patients randomized to TAGRISSO as compared to erlotinib or gefitinib (see Table 16 and Figure 4). The final analysis of overall survival demonstrated a statistically significant improvement in overall survival in patients randomized to TAGRISSO compared to erlotinib or gefitinib (see Table 1716 and Figure 5).
Table 16. Efficacy Results in FLAURA according to Investigator Assessment
40 unchanged lines
A total of 557 patients were randomized to either TAGRISSO in combination with pemetrexed and platinum-based chemotherapy (n=279) or TAGRISSO monotherapy (n=278). The median age was 61 years (range 26-85 years); 39% were ≥65 years and 8% were ≥75 years of age; 61% were female; 64% were Asian and 66% were never smokers. Baseline WHO PS was 0 (37%) or 1 (63%); 4% had locally advanced and 96% had metastatic NSCLC; and 1.8% received prior systemic cytotoxic chemotherapy as neoadjuvant or adjuvant therapy. With regard to EGFR tumor testing, 61% of tumors had exon 19 deletions and 38% had exon 21 L858R mutations; 0.7% of patients had tumors with both exon 19 deletions and exon 21 L858R. EGFR mutation status was centrally confirmed using the cobas® EGFR Mutation Test v2 in 96% of patients.
FLAURA2 demonstrated a statistically significant improvement in PFS for patients randomized to TAGRISSO in combination with pemetrexed and platinum-based chemotherapy as compared to TAGRISSO monotherapy (see Table 18 and Figure 6). While OS results were immature at the current analysis, with 45% of pre-specified deaths for the final analysis reported, no trend towards a detriment was observed.
FLAURA2 demonstrated a statistically significant improvement in PFS for patients randomized to TAGRISSO in combination with pemetrexed and platinum-based chemotherapy as compared to TAGRISSO monotherapy (see Table 18 and Figure 6). The final OS analysis demonstrated a statistically significant improvement in the OS for patients randomized to TAGRISSO plus pemetrexed and platinum-based chemotherapy as compared to TAGRISSO monotherapy (see Table 18 and Figure 7).
Table 18. Efficacy Results in FLAURA2 according to Investigator Assessment
7 unchanged lines
p-value | <0.0001
Overall Survival (OS)
Number (%) of deaths | 144 (52) | 171 (62)
Median OS in months (95% CI) | 47.5 (41.0, NE) | 37.6 (33.2, 43.2)
Hazard Ratio (95% CI) | 0.77 (0.61, 0.96)
p-value | 0.0202
Overall Response Rate (ORR)
6 unchanged lines
Figure 6. Kaplan-Meier Curves of PFS by Investigator Assessment in FLAURA2
Figure 7. Kaplan-Meier Curves of Overall Survival in FLAURA2
All patients had available baseline brain scans reviewed by BICR using modified RECIST; 78/557 (14%) patients had CNS measurable lesions. Results of pre-specified exploratory analyses of CNS ORR and DoR by BICR are summarized in Table 19.
13 unchanged lines
A total of 419 patients were randomized 2:1 to receive TAGRISSO (n=279) or platinum-based doublet chemotherapy (n=140). Randomization was stratified by ethnicity (Asian vs other races). Patients in the TAGRISSO arm received TAGRISSO 80 mg orally once daily until intolerance to therapy, disease progression, or investigator determination that the patient was no longer benefiting from treatment. Patients in the chemotherapy arm received pemetrexed 500 mg/m2 with carboplatin AUC5 or pemetrexed 500 mg/m2 with cisplatin 75 mg/m2 on Day 1 of every 21-day cycle for up to 6 cycles. Patients whose disease had not progressed after four cycles of platinum-based chemotherapy could have received pemetrexed maintenance therapy (pemetrexed 500 mg/m2 on Day 1 of every 21-day cycle).
The major efficacy outcome measure was PFS according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) by investigator assessment. Additional efficacy outcome measures included ORR, DoR, and OS. Patients randomized to the chemotherapy arm who had radiological progression according to both investigator and BICR were permitted to cross -over to receive treatment with TAGRISSO.
The baseline demographic and disease characteristics of the overall trial population were: median age 62 years (range: 20-90 years), ≥75 years old (15%), female (64%), White (32%), Asian (65%), never smoker (68%), WHO performance status 0 or 1 (100%). Fifty-four percent (54%) of patients had extra-thoracic visceral metastases, including 34% with central nervous system (CNS) metastases (including 11% with measurable CNS metastases) and 23% with liver metastases. Forty-two percent (42%) of patients had metastatic bone disease.
In AURA3, there was a statistically significant improvement in PFS in the patients randomized to TAGRISSO compared to chemotherapy (see Table 20 and Figure 78). No statistically significant difference was observed between the treatment arms at final OS analysis. At the time of the final OS analysis, 99 patients (71%) randomized to chemotherapy had crossed over to TAGRISSO treatment.
Table 20. Efficacy Results According to Investigator Assessment in AURA3
5 unchanged lines
Median PFS in months (95% CI) | 10.1 (8.3, 12.3) | 4.4 (4.2, 5.6)
Hazard Ratio (95% CI ) | 0.30 (0.23,0.41)
p-value | <0.001
11 unchanged lines
Median in months (95% CI) | 11.0 (8.6, 12.6) | 4.2 (3.0, 5.9)
Figure 78. Kaplan-Meier Curves of PFS by Investigator Assessment in AURA3
In a supportive analysis of PFS according to BICR, median PFS was 11 months in the TAGRISSO arm compared to 4.2 months in the chemotherapy arm (HR 0.28; 95% CI: 0.20, 0.38).
10 unchanged lines

Patient counseling information

Changed145 words added, 300 removed
2 unchanged lines
Interstitial Lung Disease/Pneumonitis
•Inform patients of the risks of severe or fatal ILD, including pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see Warnings and Precautions (5.1)].
QTc Interval Prolongation
•Inform patients of symptoms that may be indicative of significant QTc prolongation including dizziness, lightheadedness, and syncope. Advise patients to report these symptoms and to inform their physician about the use of any heart or blood pressure medications [see Warnings and Precautions (5.2) ].
Cardiomyopathy
•Inform patients that TAGRISSO can cause cardiomyopathy. Advise patients to immediately report any signs or symptoms of heart failure to their healthcare provider [see Warnings and Precautions (5.3) ].
Keratitis
•Advise patients to contact their healthcare provider immediately if they develop eye symptoms (eye inflammation, lacrimation, light sensitivity, eye pain, red eye or changes in vision) [see Warnings and Precautions (5.4) ].
Erythema Multiforme Major, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis
•Inform patients of signs and symptoms that may be indicative of EMM, SJS, or TEN. Advise patients to contact their healthcare provider immediately if they develop target lesions or severe blistering or peeling of skin [see Warnings and Precautions (5.5) ].
Cutaneous Vasculitis
•Inform patients of signs and symptoms that may be indicative of cutaneous vasculitis. Advise patients to contact their healthcare provider immediately if they develop multiple, non-blanching red papules on their forearms, lower legs, or buttocks or large hives on their trunk that do not go away within 24 hours and develop a bruised appearance [see Warnings and Precautions (5.6)].
Aplastic Anemia
•Inform patients of signs and symptoms of aplastic anemia including but not limited to new or persistent fevers, bruising, bleeding, pallor, infection, tiredness or weakness. Advise patients to contact their healthcare provider immediately if signs and symptoms suggestive of aplastic anemia develop [see Warnings and Precautions (5.7)].
Myalgia or Myositis with Creatine Phosphokinase Elevation
Advise patients that TAGRISSO can cause creatine phosphokinase (CPK) elevations. Advise patients to inform their healthcare provider if they experience unexplained muscle pain or tenderness [see Warnings and Precautions (5.8)].
Embryo-Fetal Toxicity
•Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider if they become pregnant or if pregnancy is suspected, while taking TAGRISSO [see Warnings and Precautions (5.89) and Use in Specific Populations (8.1)].
Females and Males of Reproductive Potential
•Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose [see Use in Specific Populations (8.3)].
•Advise males to use effective contraception during treatment and for 4 months after the last dose of TAGRISSO [see Use in Specific Populations (8.3)].
Lactation
•Advise women not to breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose [see Use in Specific Populations (8.2)].
Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850
TAGRISSO is a registered trademark of the AstraZeneca group of companies.
©AstraZeneca 20242026
Patient Medication Information
PATIENT INFORMATION TAGRISSO® (tuh-GRISS-oh) (osimertinib) tablets
What is the most important information I should know about TAGRISSO? TAGRISSO may cause serious side effects, including: • Lung problems. TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever. • Heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint. • Eye problems. TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO. • Skin problems. TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin. • Inflammation of the blood vessels in your skin. TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised. • Blood and bone marrow problems. TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. Tell your healthcare provider right away if you develop any signs or symptoms of blood and bone marrow problems, including:
oa new fever or fever that does not go away (temperature 100.4°F or higher) | oeasy bruising or bleeding that will not stop ounusually pale skin | oinfection otiredness oweakness
See “What are the possible side effects of TAGRISSO?” for more information about side effects.
•Muscle pain, tenderness or weakness (myalgia and myositis). TAGRISSO may cause myalgia or myositis with an increase in the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to monitor your levels of CPK during treatment with TAGRISSO. Tell your healthcare provider if you develop any unexplained muscle pain, tenderness, or weakness during your treatment with TAGRISSO. See “What are the possible side effects of TAGRISSO?” for more information about side effects.
What is TAGRISSO? TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s): •to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, or •when your lung cancer has spread to nearby tissues (locally advanced) that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, or •as your first treatment when your lung cancer has spread to other parts of the body (metastatic), or •in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic). •when your lung cancer has spread to other parts of the body (metastatic), and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working. Your healthcare provider will perform a test to make sure that TAGRISSO is right for you. It is not known if TAGRISSO is safe and effective in children.
Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you: •have lung or breathing problems other than your lung cancer. •have heart problems, including a condition called long QTc syndrome. •have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium. •have a history of eye problems. •are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant. •o Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO. •o Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO. •are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.
Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you: •have lung or breathing problems other than your lung cancer. •have heart problems, including a condition called long QTc syndrome. •have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium. •have a history of eye problems. •are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant. • Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO. • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO. •are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.
How should I take TAGRISSO? •Take TAGRISSO exactly as your healthcare provider tells you to take it. •Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects. •Take TAGRISSO 1 time each day. •You can takeTake TAGRISSO with or without food. •If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time. • If you cannot swallow TAGRISSO tablets whole: •PlaceoPlace your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids. •StiroStir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture. •DrinkoDrink the TAGRISSO and water mixture right away. •AddoAdd 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO. • If you have a nasogastric (NG) tube: •FollowoFollow the same instructions for mixing TAGRISSO tablets in a container that contains 15 mL of water. Do not use carbonated water or any other liquids. •StiroStir the TAGRISSO tablets and water until the TAGRISSO tablets are in small pieces (the tablets will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture. •AddoAdd another 15 mL of water into the container to make sure no pieces of TAGRISSO tablet remain. •GiveoGive the TAGRISSO tablet and water mixture using the NG tube manufacturer instructions within 30 minutes. AddoAdd another 30 mL of water into the syringe and give the water and any remaining TAGRISSO through the NG tube to make sure that all of the medicine is given. Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given.
What are the possible side effects of TAGRISSO? TAGRISSO may cause serious side effects: • See “What is the most important information I should know about TAGRISSO?” The most common side effects of TAGRISSO when given alone include:
•low white blood cell counts •low platelet counts •low red blood cell counts (anemia) •diarrhea •rash | •muscle, bone, or joint pain •changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail | •dry skin •mouth sores •tiredness
The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include:
•low white blood cell counts •lung problems •low platelet counts •rash •diarrhea | •changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail | Cough•cough •COVID-19
The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include:
•low white blood cell counts •low platelet counts •rash •diarrhea •mouth sores | •changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail | •dry skin •increase of a substance in the blood called creatinine
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store TAGRISSO? •Store TAGRISSO at room temperature between 68°F to 77°F (20°C to 25°C). •Safely throw away medicine that is out of date or that you no longer need. Keep TAGRISSO and all medicines out of the reach of children.
General information about the safe and effective use of TAGRISSO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAGRISSO that is written for health professionals.
What are the ingredients in TAGRISSO? Active ingredient: osimertinib Inactive ingredients: mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black. Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 © AstraZeneca 20242026 For more information, go to www.Tagrisso.com or call 1-800-236-9933.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 09/20242026

Unchanged: Dosage forms and strengths, Contraindications, Use in specific populations, Description, Clinical pharmacology, Nonclinical toxicology, How supplied, PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 40 mg, PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 80 mg, Package/label principal display panel.

Every version

33 versions of set 5e81b4a7-b971-45e1-9c31-29cea8c87ce7, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.